GeneDx Holdings Corp.
About GeneDx Holdings Corp.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $427.5M
- Net income
- -$21.0M
- Total assets
- $523.7M
- Market cap
- $1.6B
- Gross margin
- 69.7%
- Operating margin
- -3.1%
- Net margin
- -4.9%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $427.5M
- Cost of revenue
- $129.4M
- Gross profit
- $298.2M
- Operating expenses
- $311.2M
- Operating income
- -$13.1M
- Income tax
- -$116.0K
- Net income
- -$21.0M
- EPS (basic)
- $-0.73
- EPS (diluted)
- $-0.73
Balance sheet
- Total assets
- $523.7M
- Current assets
- $268.3M
- Total liabilities
- $215.5M
- Current liabilities
- $108.9M
- Shareholders’ equity
- $308.2M
Cash flow
- Operating cash flow
- $33.3M
- Investing cash flow
- -$61.5M
- Financing cash flow
- $48.0M
- Net cash flow
- $19.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.6B
- EPS (diluted)
- $-0.73
- Shares outstanding
- 29.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 23, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $21.0M in FY2025.
- Revenue grew 111% from FY2023 to FY2025.
- Gross margin of 69.7%, net margin -4.9%.
- Trading 69% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GeneDx Holdings Corp..
Write a review
News about GeneDx Holdings Corp.
News & sentiment via Polygon.io
